MESOBLAST LIMITED - Announcements

1.09%

$2.32

Market Cap $2.950B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	31/08/21	2.73MB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	30/07/21	349.24KB	Share
MSB	Mesoblast Update on Chronic Low Back Pain Program	PRICE SENSITIVE	01/07/21	181.33KB	Share
MSB	MSB Reports Q3 Financial Results and Operational Highlight	PRICE SENSITIVE	03/06/21	479.65KB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	03/06/21	633.63KB	Share
MSB	COVID ARDS Trial Topline 60-Day Results	PRICE SENSITIVE	30/04/21	191.36KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	30/04/21	368.8KB	Share
MSB	Mesoblast Raises US$110M Led By US Strategic Investor Group	PRICE SENSITIVE	02/03/21	195.87KB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	26/02/21	806.09KB	Share
MSB	Trading Halt	PRICE SENSITIVE	26/02/21	206.93KB	Share
MSB	Mesoblast Phase 3 Chronic Low Back Pain Results	PRICE SENSITIVE	11/02/21	360.41KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	29/01/21	209.47KB	Share
MSB	Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF	PRICE SENSITIVE	11/01/21	126.77KB	Share
MSB	Mesoblast Update on COVID-19 ARDS Trial	PRICE SENSITIVE	18/12/20	106.84KB	Share
MSB	Trading halt	PRICE SENSITIVE	16/12/20	155.18KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	16/12/20	116.28KB	Share
MSB	Mesoblast Phase 3 Chronic Heart Failure Results	PRICE SENSITIVE	15/12/20	130.08KB	Share
MSB	Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS	PRICE SENSITIVE	02/12/20	116.21KB	Share
MSB	Novartis and Mesoblast Remestemcel-L Collaboration	PRICE SENSITIVE	20/11/20	147.21KB	Share
MSB	First Quarter Results Presentation	PRICE SENSITIVE	20/11/20	2.18MB	Share
MSB	MSB Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	20/11/20	271.6KB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	20/11/20	590.73KB	Share
MSB	DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial	PRICE SENSITIVE	11/11/20	117.63KB	Share
MSB	COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C	PRICE SENSITIVE	29/10/20	192.37KB	Share
MSB	Update on BLA for Graft Versus Host Disease	PRICE SENSITIVE	02/10/20	93.31KB	Share
MSB	Trading Halt	PRICE SENSITIVE	01/10/20	153.58KB	Share
MSB	MSB Wins Fierce Biotech Innovation Award for Remestemcel-L	PRICE SENSITIVE	15/09/20	109.05KB	Share
MSB	DSMB Recommends Continuation of Phase 3 COVID-19 Trial	PRICE SENSITIVE	04/09/20	110.61KB	Share
MSB	MSB Annual Financial Results and Operational Progress	PRICE SENSITIVE	27/08/20	270.6KB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	27/08/20	2.48MB	Share
MSB	ODAC Votes in Favor of Remestemcel-L for GvHD	PRICE SENSITIVE	14/08/20	117.69KB	Share
MSB	Trading Halt	PRICE SENSITIVE	13/08/20	155.11KB	Share
MSB	Update on Scheduled FDA Advisory Committee Meeting	PRICE SENSITIVE	11/08/20	109.23KB	Share
MSB	COVID-19/GVHD Update, Quarterly Report and Appendix 4C	PRICE SENSITIVE	30/07/20	230.46KB	Share
MSB	FDA Advisory Committee Sets Review Date for Remestemcel-L	PRICE SENSITIVE	21/07/20	108.87KB	Share
MSB	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
MSB	Remestemcel-L Improves Outcomes in Inflammatory Lung Disease	PRICE SENSITIVE	01/06/20	116.33KB	Share
MSB	MSB Reports Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	28/05/20	281.8KB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	28/05/20	614.49KB	Share
MSB	MSB Completes Financing For Covid-19 ARDS Manufacturing	PRICE SENSITIVE	13/05/20	144.68KB	Share
MSB	Trading Halt	PRICE SENSITIVE	11/05/20	170.3KB	Share
MSB	Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment	PRICE SENSITIVE	30/04/20	140.07KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/20	193.38KB	Share
MSB	83% Survival in COVID-19 ARDS Patients with Remestemcel-L	PRICE SENSITIVE	24/04/20	144.87KB	Share
MSB	US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial	PRICE SENSITIVE	09/04/20	95.91KB	Share
MSB	FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients	PRICE SENSITIVE	06/04/20	89.95KB	Share
MSB	FDA Accepts BLA for RYONCIL and Agrees to Priority Review	PRICE SENSITIVE	01/04/20	92.3KB	Share
MSB	Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease	PRICE SENSITIVE	10/03/20	98.41KB	Share
MSB	Mesoblast Provides Half Year Results and Corporate Update	PRICE SENSITIVE	27/02/20	223.76KB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	27/02/20	757.72KB	Share
MSB	Mesoblast Submits Completed BLA for Ryoncil to US FDA	PRICE SENSITIVE	03/02/20	114.77KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/20	219.65KB	Share
MSB	MSB Files GvHD Clinical Efficacy and Safety Data with US FDA	PRICE SENSITIVE	02/01/20	128.07KB	Share
MSB	DMC Completes Final Review of Phase 3 Heart Failure Trial	PRICE SENSITIVE	18/12/19	119.18KB	Share
MSB	CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)	PRICE SENSITIVE	17/12/19	122.93KB	Share
MSB	CHF P3 Trial Accrues Sufficient Primary Endpoint Events	PRICE SENSITIVE	17/12/19	122.57KB	Share
MSB	MSB Provides Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	26/11/19	309.78KB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	26/11/19	502.82KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	212.78KB	Share
MSB	MSB and Lonza Enter GVHD Commercial Manufacturing Agreement	PRICE SENSITIVE	17/10/19	94.01KB	Share
MSB	Mesoblast Raises A$75 Million	PRICE SENSITIVE	03/10/19	112.24KB	Share
MSB	Trading Halt	PRICE SENSITIVE	01/10/19	288.32KB	Share
MSB	Grunenthal and MSB Enter Strategic Partnership for Back Pain	PRICE SENSITIVE	10/09/19	127.73KB	Share
MSB	Mesoblast Reports on Annual Results	PRICE SENSITIVE	30/08/19	243.33KB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	30/08/19	3.68MB	Share
MSB	FDA Guidance on Clinical Pathway for LVAD Market Application	PRICE SENSITIVE	27/08/19	108.18KB	Share
MSB	Appendix 4C - Quarterly, Strong Commercialization Revenues	PRICE SENSITIVE	31/07/19	198.68KB	Share
MSB	Circulation Research Highlights MSB Heart Failure Therapy	PRICE SENSITIVE	25/07/19	125.8KB	Share
MSB	FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs	PRICE SENSITIVE	24/06/19	134.93KB	Share
MSB	MSB Expands JCR Partnership To Brain Disease In Newborns	PRICE SENSITIVE	11/06/19	94.26KB	Share
MSB	MSB Provides Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	31/05/19	184.53KB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	31/05/19	536.5KB	Share
MSB	Mesoblast Initiates Rolling Submission of BLA for GvHD	PRICE SENSITIVE	30/05/19	94.56KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	134.84KB	Share
MSB	MoU for Confirmatory Trial for GI Bleeding in LVAD Patients	PRICE SENSITIVE	27/03/19	107.1KB	Share
MSB	MSB Licensee Files For Skin Disease Marketing Approval	PRICE SENSITIVE	25/03/19	91.43KB	Share
MSB	Mesoblast Provides Half Year Results and Corporate Update	PRICE SENSITIVE	21/02/19	187.06KB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	21/02/19	693.79KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	133.52KB	Share
MSB	MSB Draws US$15 Million From Existing Facility	PRICE SENSITIVE	14/01/19	122.84KB	Share
MSB	P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment	PRICE SENSITIVE	07/01/19	88.48KB	Share
MSB	Response to ASX query	PRICE SENSITIVE	05/12/18	421.44KB	Share
MSB	MSB Provides Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	16/11/18	304.15KB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	16/11/18	468.25KB	Share
MSB	LVAD Results Webcast Presentation	PRICE SENSITIVE	13/11/18	1.58MB	Share
MSB	LVAD Trial Results Provide Potential Regulatory Pathway	PRICE SENSITIVE	12/11/18	153.14KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	12/11/18	115.8KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	124.88KB	Share
MSB	MSB Expands Partnership With JCR For Skin Disease	PRICE SENSITIVE	24/10/18	92.16KB	Share
MSB	Completion of Tasly Transaction, and Appendix 3B	PRICE SENSITIVE	12/10/18	302.01KB	Share
MSB	Day 180 Survival Outcomes In aGvHD Phase 3 Trial	PRICE SENSITIVE	20/09/18	97.85KB	Share
MSB	Tasly Receives Approvals For Transaction With MSB	PRICE SENSITIVE	17/09/18	71.22KB	Share
MSB	Mesoblast Reports on Annual and Fourth Quarter Results	PRICE SENSITIVE	30/08/18	219.59KB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	30/08/18	1.6MB	Share
MSB	UPDATE ON TASLY TRANSACTION	PRICE SENSITIVE	29/08/18	89.39KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	117.52KB	Share
MSB	MSB Enters Into Cardiovascular Alliance For China With Tasly	PRICE SENSITIVE	17/07/18	80.49KB	Share
MSB	MSB Enters Into US$50M Financing With NovaQuest Capital	PRICE SENSITIVE	02/07/18	80.37KB	Share
MSB	Key Day 100 Survival Results In P3 GvHD Trial	PRICE SENSITIVE	21/06/18	76.22KB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	31/05/18	515.82KB	Share

MSB Preliminary Final Report including Appendix 4E
31/08/21	PRICE SENSITIVE	2.73MB	Share
MSB Appendix 4C Quarterly Activity Report
30/07/21	PRICE SENSITIVE	349.24KB	Share
MSB Mesoblast Update on Chronic Low Back Pain Program
01/07/21	PRICE SENSITIVE	181.33KB	Share
MSB MSB Reports Q3 Financial Results and Operational Highlight
03/06/21	PRICE SENSITIVE	479.65KB	Share
MSB Third Quarter Financial Results on Form 6-K
03/06/21	PRICE SENSITIVE	633.63KB	Share
MSB COVID ARDS Trial Topline 60-Day Results
30/04/21	PRICE SENSITIVE	191.36KB	Share
MSB Appendix 4C Quarterly Activity Report
30/04/21	PRICE SENSITIVE	368.8KB	Share
MSB Mesoblast Raises US$110M Led By US Strategic Investor Group
02/03/21	PRICE SENSITIVE	195.87KB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
26/02/21	PRICE SENSITIVE	806.09KB	Share
MSB Trading Halt
26/02/21	PRICE SENSITIVE	206.93KB	Share
MSB Mesoblast Phase 3 Chronic Low Back Pain Results
11/02/21	PRICE SENSITIVE	360.41KB	Share
MSB Appendix 4C Quarterly Activity Report
29/01/21	PRICE SENSITIVE	209.47KB	Share
MSB Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
11/01/21	PRICE SENSITIVE	126.77KB	Share
MSB Mesoblast Update on COVID-19 ARDS Trial
18/12/20	PRICE SENSITIVE	106.84KB	Share
MSB Trading halt
16/12/20	PRICE SENSITIVE	155.18KB	Share
MSB Pause in Trading
16/12/20	PRICE SENSITIVE	116.28KB	Share
MSB Mesoblast Phase 3 Chronic Heart Failure Results
15/12/20	PRICE SENSITIVE	130.08KB	Share
MSB Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
02/12/20	PRICE SENSITIVE	116.21KB	Share
MSB Novartis and Mesoblast Remestemcel-L Collaboration
20/11/20	PRICE SENSITIVE	147.21KB	Share
MSB First Quarter Results Presentation
20/11/20	PRICE SENSITIVE	2.18MB	Share
MSB MSB Q1 Financial Results and Operational Highlights
20/11/20	PRICE SENSITIVE	271.6KB	Share
MSB First Quarter Financial Results on Form 6-K
20/11/20	PRICE SENSITIVE	590.73KB	Share
MSB DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
11/11/20	PRICE SENSITIVE	117.63KB	Share
MSB COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
29/10/20	PRICE SENSITIVE	192.37KB	Share
MSB Update on BLA for Graft Versus Host Disease
02/10/20	PRICE SENSITIVE	93.31KB	Share
MSB Trading Halt
01/10/20	PRICE SENSITIVE	153.58KB	Share
MSB MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
15/09/20	PRICE SENSITIVE	109.05KB	Share
MSB DSMB Recommends Continuation of Phase 3 COVID-19 Trial
04/09/20	PRICE SENSITIVE	110.61KB	Share
MSB MSB Annual Financial Results and Operational Progress
27/08/20	PRICE SENSITIVE	270.6KB	Share
MSB Preliminary Final Report including Appendix 4E
27/08/20	PRICE SENSITIVE	2.48MB	Share
MSB ODAC Votes in Favor of Remestemcel-L for GvHD
14/08/20	PRICE SENSITIVE	117.69KB	Share
MSB Trading Halt
13/08/20	PRICE SENSITIVE	155.11KB	Share
MSB Update on Scheduled FDA Advisory Committee Meeting
11/08/20	PRICE SENSITIVE	109.23KB	Share
MSB COVID-19/GVHD Update, Quarterly Report and Appendix 4C
30/07/20	PRICE SENSITIVE	230.46KB	Share
MSB FDA Advisory Committee Sets Review Date for Remestemcel-L
21/07/20	PRICE SENSITIVE	108.87KB	Share
MSB S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
MSB Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
01/06/20	PRICE SENSITIVE	116.33KB	Share
MSB MSB Reports Q3 Financial Results and Operational Highlights
28/05/20	PRICE SENSITIVE	281.8KB	Share
MSB Third Quarter Financial Results on Form 6-K
28/05/20	PRICE SENSITIVE	614.49KB	Share
MSB MSB Completes Financing For Covid-19 ARDS Manufacturing
13/05/20	PRICE SENSITIVE	144.68KB	Share
MSB Trading Halt
11/05/20	PRICE SENSITIVE	170.3KB	Share
MSB Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
30/04/20	PRICE SENSITIVE	140.07KB	Share
MSB Appendix 4C - quarterly
29/04/20	PRICE SENSITIVE	193.38KB	Share
MSB 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
24/04/20	PRICE SENSITIVE	144.87KB	Share
MSB US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
09/04/20	PRICE SENSITIVE	95.91KB	Share
MSB FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
06/04/20	PRICE SENSITIVE	89.95KB	Share
MSB FDA Accepts BLA for RYONCIL and Agrees to Priority Review
01/04/20	PRICE SENSITIVE	92.3KB	Share
MSB Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
10/03/20	PRICE SENSITIVE	98.41KB	Share
MSB Mesoblast Provides Half Year Results and Corporate Update
27/02/20	PRICE SENSITIVE	223.76KB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
27/02/20	PRICE SENSITIVE	757.72KB	Share
MSB Mesoblast Submits Completed BLA for Ryoncil to US FDA
03/02/20	PRICE SENSITIVE	114.77KB	Share
MSB Appendix 4C - quarterly
29/01/20	PRICE SENSITIVE	219.65KB	Share
MSB MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
02/01/20	PRICE SENSITIVE	128.07KB	Share
MSB DMC Completes Final Review of Phase 3 Heart Failure Trial
18/12/19	PRICE SENSITIVE	119.18KB	Share
MSB CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
17/12/19	PRICE SENSITIVE	122.93KB	Share
MSB CHF P3 Trial Accrues Sufficient Primary Endpoint Events
17/12/19	PRICE SENSITIVE	122.57KB	Share
MSB MSB Provides Q1 Financial Results and Operational Highlights
26/11/19	PRICE SENSITIVE	309.78KB	Share
MSB First Quarter Financial Results on Form 6-K
26/11/19	PRICE SENSITIVE	502.82KB	Share
MSB Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	212.78KB	Share
MSB MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
17/10/19	PRICE SENSITIVE	94.01KB	Share
MSB Mesoblast Raises A$75 Million
03/10/19	PRICE SENSITIVE	112.24KB	Share
MSB Trading Halt
01/10/19	PRICE SENSITIVE	288.32KB	Share
MSB Grunenthal and MSB Enter Strategic Partnership for Back Pain
10/09/19	PRICE SENSITIVE	127.73KB	Share
MSB Mesoblast Reports on Annual Results
30/08/19	PRICE SENSITIVE	243.33KB	Share
MSB Preliminary Final Report including Appendix 4E
30/08/19	PRICE SENSITIVE	3.68MB	Share
MSB FDA Guidance on Clinical Pathway for LVAD Market Application
27/08/19	PRICE SENSITIVE	108.18KB	Share
MSB Appendix 4C - Quarterly, Strong Commercialization Revenues
31/07/19	PRICE SENSITIVE	198.68KB	Share
MSB Circulation Research Highlights MSB Heart Failure Therapy
25/07/19	PRICE SENSITIVE	125.8KB	Share
MSB FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
24/06/19	PRICE SENSITIVE	134.93KB	Share
MSB MSB Expands JCR Partnership To Brain Disease In Newborns
11/06/19	PRICE SENSITIVE	94.26KB	Share
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/19	PRICE SENSITIVE	184.53KB	Share
MSB Third Quarter Financial Results on Form 6-K
31/05/19	PRICE SENSITIVE	536.5KB	Share
MSB Mesoblast Initiates Rolling Submission of BLA for GvHD
30/05/19	PRICE SENSITIVE	94.56KB	Share
MSB Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	134.84KB	Share
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
27/03/19	PRICE SENSITIVE	107.1KB	Share
MSB MSB Licensee Files For Skin Disease Marketing Approval
25/03/19	PRICE SENSITIVE	91.43KB	Share
MSB Mesoblast Provides Half Year Results and Corporate Update
21/02/19	PRICE SENSITIVE	187.06KB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
21/02/19	PRICE SENSITIVE	693.79KB	Share
MSB Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	133.52KB	Share
MSB MSB Draws US$15 Million From Existing Facility
14/01/19	PRICE SENSITIVE	122.84KB	Share
MSB P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
07/01/19	PRICE SENSITIVE	88.48KB	Share
MSB Response to ASX query
05/12/18	PRICE SENSITIVE	421.44KB	Share
MSB MSB Provides Q1 Financial Results and Operational Highlights
16/11/18	PRICE SENSITIVE	304.15KB	Share
MSB First Quarter Financial Results on Form 6-K
16/11/18	PRICE SENSITIVE	468.25KB	Share
MSB LVAD Results Webcast Presentation
13/11/18	PRICE SENSITIVE	1.58MB	Share
MSB LVAD Trial Results Provide Potential Regulatory Pathway
12/11/18	PRICE SENSITIVE	153.14KB	Share
MSB Pause in Trading
12/11/18	PRICE SENSITIVE	115.8KB	Share
MSB Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	124.88KB	Share
MSB MSB Expands Partnership With JCR For Skin Disease
24/10/18	PRICE SENSITIVE	92.16KB	Share
MSB Completion of Tasly Transaction, and Appendix 3B
12/10/18	PRICE SENSITIVE	302.01KB	Share
MSB Day 180 Survival Outcomes In aGvHD Phase 3 Trial
20/09/18	PRICE SENSITIVE	97.85KB	Share
MSB Tasly Receives Approvals For Transaction With MSB
17/09/18	PRICE SENSITIVE	71.22KB	Share
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/18	PRICE SENSITIVE	219.59KB	Share
MSB Preliminary Final Report including Appendix 4E
30/08/18	PRICE SENSITIVE	1.6MB	Share
MSB UPDATE ON TASLY TRANSACTION
29/08/18	PRICE SENSITIVE	89.39KB	Share
MSB Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	117.52KB	Share
MSB MSB Enters Into Cardiovascular Alliance For China With Tasly
17/07/18	PRICE SENSITIVE	80.49KB	Share
MSB MSB Enters Into US$50M Financing With NovaQuest Capital
02/07/18	PRICE SENSITIVE	80.37KB	Share
MSB Key Day 100 Survival Results In P3 GvHD Trial
21/06/18	PRICE SENSITIVE	76.22KB	Share
MSB Third Quarter Financial Results on Form 6-K
31/05/18	PRICE SENSITIVE	515.82KB	Share

REFRESH

First 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.32		Change 0.025(1.09%)		Mkt cap ! $2.950B

Open	High	Low	Value	Volume
$2.31	$2.33	$2.30	$1.765M	762.8K

Buyers (Bids)

No.	Vol.	Price($)
31	48128	$2.31

Sellers (Offers)

Price($)	Vol.	No.
$2.32	100428	24

View Market Depth

No.	Vol.	Price($)
42	38264	2.300
18	95742	2.290
17	122809	2.280
15	77923	2.270
13	104222	2.260

Price($)	Vol.	No.
2.310	127558	23
2.320	100252	20
2.330	113391	23
2.340	82870	14
2.350	190577	20

Last trade - 10.58am 13/08/2025 (20 minute delay)


Last $2.32		Change 0.025 ( 1.41 %)
Open	High	Low	Volume
$2.32	$2.33	$2.30	221726
Last updated 11.15am 13/08/2025 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories